People

David Cavalla has 35 years experience in various senior scientific and commercial roles within the pharmaceutical industry. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre.